Search
Metformin
go.drugbank.com/drugs/DB00331ApprovedInvestigationalMetformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes. … [A36559] Metformin was first approved in Canada in 1972,[A36552] and received subsequent FDA approval in the US in 1995.[L12207]
Categories: Drugs Used in DiabetesProducts: METFORMIN ARISTO N 500MG, METFORMIN ARISTO N 850MGDesipramine
go.drugbank.com/drugs/DB01151ApprovedThe antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. … In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake.
Synonyms: N-(3-methylaminopropyl)iminobibenzylUblituximab
go.drugbank.com/drugs/DB11850ApprovedInvestigational[A244210] Ublituximab is a chimeric anti-CD20 IgG1κ antibody produced in the rat YB2/0 cell line to target a unique epitope and enhance ADCC compared to other approved anti-CD20 antibodies such as [rituximab … CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions.
Antigen peptide transporter 1
go.drugbank.com/bio_entities/BE0003109TransporterHumansIn complex with TAP2 mediates unidirectional translocation of peptide antigens from cytosol to endoplasmic reticulum (ER) for loading onto MHC class I (MHCI) molecules (PubMed:25377891, PubMed:25656091
Synonyms: Peptide transporter involved in antigen processing 1Idelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalFor the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other … co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.
Categories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitorsAncestim
go.drugbank.com/drugs/DB09103ApprovedWithdrawn[T68] It was also approved by Health Canada in 1999 but it is currently under the status of canceled post-market.[L1087] … Ancestim was developed by Amgen and sold to Biovitrium in December 2008. It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes.
Selinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigational[L7123] Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of … Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound.
Lifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalThe ophthalmic solution was approved in July, 2016 under the trade name Xiidra. … It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting [A18805].
Categories: Compounds used in a research, industrial, or household settingAmivantamab
go.drugbank.com/drugs/DB16695ApprovedInvestigationalFDA approved the subcutaneous formulation, RYBREVANT FASPRO™, across all existing and expanded indications of amivantamab, including its use as a first-line, chemotherapy-free combination regimen with … [A235103,A235123] Patients with NSCLC with exon 20 insertion mutations in EGFR do not respond to tyrosine kinase inhibitors, and were generally treated with platinum-based therapy.
Soybean oil
go.drugbank.com/drugs/DB09422ApprovedInvestigationalIt is used as a cooking oil and lipid emulsion for parenteral nutrition in clinical settings. Soybean oil-based lipid emulsion is the only FDA-approved lipid formulation for clinical use. … It is a complex mixture of triglycerides where per 100 g, soybean oil has 16 g of saturated fat, 23 g of monounsaturated fat, and 58 g of polyunsaturated fat.
Mixtures: Liposyn II Inj 10%, Liposyn IIProducts: LIPOFUNDIN 20 %N, LIPOFUNDIN 10 %N